BioMarin Pharmaceutical announced that it is considering a price between $2 million and $3 million for its gene therapy Valrox, or valoctocogene roxaparvovec, a treatment for hemophilia A. BioMarin is also considering other payment options such as pay for performance.
BioMarin's hemophilia A gene therapy could cost between $2M and $3M
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.